Loading...
NPI 1821446550 · Dallas, TX · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Tdm Laboratories Of Katy, LLC is a clinical medical laboratory provider located in Dallas, Texas. This profile covers 16 Medicare and 16 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Tdm Laboratories Of Katy, LLC |
| Address | 5510 Abrams Rd Ste 119b |
| City | Dallas |
| State | TX |
| ZIP | 75214 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | June 3, 2016 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $9.3M |
| Medicaid | $105.1K |
TDM LABORATORIES OF KATY, LLC presents the profile of a molecular diagnostic clinical laboratory: its highest-volume CPT/HCPCS are dominated by amplified nucleic acid probe and multiplex respiratory panel testing (examples include 87798, 87631 and 87502), indicating operational focus on NAAT-based infectious disease diagnostics rather than routine chemistry or anatomic pathology work. The top Medicare codes’ descriptions (broad amplified probe testing, multi-pathogen respiratory panels, influenza subtyping) point to a lab organized around high-throughput molecular assays for respiratory and other infectious agents.
Revenue concentration on Medicare is pronounced: the provider reports $9.3M in lifetime Medicare revenue and the precomputed top-3 Medicare codes account for 62.6% of that Medicare revenue, with 87798 contributing 41.0%, 87150 contributing 13.6%, and 87631 contributing 8.0%. This concentration means a majority of its Medicare income is driven by a small set of high-volume molecular testing codes.
Medicaid revenue is small in scale relative to Medicare: lifetime Medicaid revenue is $105.1K, and the precomputed top-3 Medicaid codes account for 51.8% of the provider’s Medicaid revenue, led by 87798 at 35.2%, followed by 87150 at 9.9% and 87631 at 6.7%. The Medicaid code mix mirrors Medicare in test types but represents only a very small fraction of total lifetime billed revenue, indicating Medicare as the primary commercial payer relationship.
On payer mix, Medicare overwhelmingly dominates the provider’s billing footprint ($9.3M Medicare vs. $105.1K Medicaid), making TDM effectively Medicare-driven in scale and commercial importance. Medicaid activity is present across similar molecular codes but is not material to the provider’s overall revenue base.
Competitive standing on Medicare shows national-level dominance for several specific assays: 87798 ranks #11 of 1319 providers nationally (99th percentile; extreme outlier) and 87631 ranks #4 of 636 providers nationally (100th percentile; extreme outlier), with other top codes such as 87502 and multiple respiratory/infectious-agent codes also listed as extreme outliers or high-percentile performers. These rankings indicate the provider is a major national volume outlier on select molecular tests rather than a typical low-volume local lab for those services.
By contrast, the provider’s Medicaid positioning within Texas is strong but more modest: 87798 ranks #26 of 243 in-state (90th percentile; typical, unremarkable volume), 87150 ranks #5 of 52 (92nd percentile; typical, unremarkable volume), and several other codes sit in the 84th–95th percentile range in-state with a few noted as notably above typical state volume. This pattern suggests solid in-state presence for similar test types but not the same extreme market dominance seen in Medicare national rankings.
Statistical outlier signals are concentrated in Medicare: several high-revenue Medicare codes are labeled in the data as “extreme outlier” or “notably above typical national volume,” which corroborates the lab’s unusually high national throughput for specific NAAT assays. That concentration of high-percentile, outlier-volume codes is an operational strength for high-volume molecular testing but also implies sensitivity to changes in reimbursement, coding policy, or contract sourcing for those specific assays.
The provider has been NPI-enumerated since 2016-06-03 (~10 years ago), indicating roughly a decade of activity during which it has scaled to high national volumes on select molecular diagnostic codes. Ten years of operation combined with the observed code mix and high Medicare concentration suggests an established specialized lab footprint rather than a new market entrant.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
16 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 111,680 | $30 | $3.8M |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 36,940 | $30 | $1.3M |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 5,290 | $140 | $740.7K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 5,290 | $90 | $497.4K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 13,120 | $30 | $446.1K |
| 87634 | The lab analyst performs a test for respiratory syncytial virus (RSV) antigen detection using amplified nucleic acid probe technique. | 5,290 | $70 | $365K |
| 87529 | The lab analyst performs a test for Herpes simplex virus, HSV, using amplified nucleic acid probe technique. HSV causes clusters of blisters, or vesicles, on different parts of the body and spreads… | 10,580 | $30 | $359.8K |
| 87652 | The lab analyst performs a test to quantify infection with Streptococcus, group A, using nucleic acid probe technique. | 6,560 | $40 | $269.1K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 6,560 | $30 | $223.1K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 6,560 | $30 | $223K |
Showing 1–10 of 16
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 16 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
16 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 8,210 | $10 | $41.1K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 3,850 | $1 | $11.6K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 3,880 | $1 | $7.8K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 3,880 | $1 | $7.8K |
| 87652 | The lab analyst performs a test to quantify infection with Streptococcus, group A, using nucleic acid probe technique. | 4,350 | $1 | $4.4K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 4,350 | $1 | $4.3K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 4,350 | $1 | $4.3K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 4,350 | $1 | $4.3K |
| 87634 | The lab analyst performs a test for respiratory syncytial virus (RSV) antigen detection using amplified nucleic acid probe technique. | 3,880 | $1 | $3.9K |
| 87529 | The lab analyst performs a test for Herpes simplex virus, HSV, using amplified nucleic acid probe technique. HSV causes clusters of blisters, or vesicles, on different parts of the body and spreads… | 3,880 | $1 | $3.9K |
Showing 1–10 of 16
How this provider's Medicaid billing volume and revenue compare to other Texas providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Texas median
16 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 26 | 240 | 420 | $30 | $296.8K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 14 | 140 | 180 | $60 | $215.9K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 38 | 350 | 230 | $70 | $120.3K |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 28 | 170 | 440 | $20 | $93.6K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 56 | 420 | 340 | $20 | $73.4K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 5 | 50 | 380 | $20 | $63.4K |
| 87529 | The lab analyst performs a test for Herpes simplex virus, HSV, using amplified nucleic acid probe technique. HSV causes clusters of blisters, or vesicles, on different parts of the body and spreads… | 8 | 60 | 310 | $20 | $58.9K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 10 | 140 | 220 | $10 | $52.6K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 16 | 130 | 330 | $10 | $51.7K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 10 | 130 | 230 | $10 | $50K |
Showing 1–10 of 16
Other providers in the same ZIP code as Tdm Laboratories Of Katy, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Vivian Hoang | TX | Neurology Physician | $191.6K | $0 |
| Allison Redner | TX | Emergency Medical Services (Emergency Medicine) Physician | $126.1K | $0 |
| Maria Philip | TX | Neurology Physician | $94.5K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.